SPECT/CT imaging of high-risk atherosclerotic plaques using integrin-binding RGD dimer peptides

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yoo, Jung Sun ^b,c   Lee, Jonghwan ^d   Jung, Jae Ho ^a   Moon, Byung Seok ^a   Kim, Soonhag ^d   Lee, Byung Chul ^a,c   Kim, Sang Eun ^a,b,c  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d Catholic Kwandong University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

99MTC-IDA-D-(C(RGDFK))2; CYCLOPEPTIDE; INTEGRIN; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX;

ANIMAL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; C57BL MOUSE; DIAGNOSTIC IMAGING; KNOCKOUT MOUSE; MALE; METABOLISM; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TISSUE DISTRIBUTION;

ANIMALS; ATHEROSCLEROSIS; INTEGRINS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; PLAQUE, ATHEROSCLEROTIC; PROTEIN BINDING; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84934784479     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11752     Document Type: Article

References (36)

1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
2. Mathers, C. D. & Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3, e442 (2006).
3. Braunwald, E. Epilogue: what do clinicians expect from imagers? J Am Coll Cardiol 47, C101-103 (2006).
4. Waxman, S., Ishibashi, F. & Muller, J. E. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation 114, 2390-2411 (2006).
5. Johnson, N. P., Kirkeeide, R. L. & Gould, K. L. Coronary anatomy to predict physiology: fundamental limits. Circ Cardiovasc Imaging 6, 817-832 (2013).
6. Hackett, D., Davies, G. & Maseri, A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J 9, 1317-1323 (1988).
7. Sanz, J. & Fayad, Z. A. Imaging of atherosclerotic cardiovascular disease. Nature 451, 953-957 (2008).
8. Owen, D. R., Lindsay, A. C., Choudhury, R. P. & Fayad, Z. A. Imaging of atherosclerosis. Annu Rev Med 62, 25-40 (2011).
9. Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325 (2011).
10. Libby, P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 368, 2004-2013 (2013).
11. Silvestre-Roig, C. et al. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res 114, 214-226 (2014).
12. Tomey, M. I., Narula, J. & Kovacic, J. C. Advances in the understanding of plaque composition and treatment options: year in review. J Am Coll Cardiol 63, 1604-1616 (2014).
13. Libby, P., DiCarli, M. & Weissleder, R. The vascular biology of atherosclerosis and imaging targets. J Nucl Med 51 Suppl 1, 33S-37S (2010).
14. Fuster, V., Lois, F. & Franco, M. Early identification of atherosclerotic disease by noninvasive imaging. Nat Rev Cardiol 7, 327-333 (2010).
15. Dobrucki, L. W. & Sinusas, A. J. PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol 7, 38-47 (2010).
16. Osborn, E. A. & Jaffer, F. A. The advancing clinical impact of molecular imaging in CVD. JACC Cardiovasc Imaging 6, 1327-1341 (2013).
17. Moreno, P. R., Purushothaman, K. R., Sirol, M., Levy, A. P. & Fuster, V. Neovascularization in human atherosclerosis. Circulation 113, 2245-2252 (2006).
18. Di Stefano, R., Felice, F. & Balbarini, A. Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 15, 1095-1106 (2009).
19. Granada, J. F. & Feinstein, S. B. Imaging of the vasa vasorum. Nat Clin Pract Cardiovasc Med 5 Suppl 2, S18-25 (2008).
20. Michel, J. B., Martin-Ventura, J. L., Nicoletti, A. & Ho-Tin-Noe, B. Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis 234, 311-319 (2014).
21. McDonald, D. M. & Choyke, P. L. Imaging of angiogenesis: from microscope to clinic. Nat Med 9, 713-725 (2003).
22. Swirski, F. K. & Nahrendorf, M. Imaging macrophage development and fate in atherosclerosis and myocardial infarction. Immunol Cell Biol 91, 297-303 (2013).
23. Mulder, W. J., Jaffer, F. A., Fayad, Z. A. & Nahrendorf, M. Imaging and Nanomedicine in Inflammatory Atherosclerosis. Sci Transl Med 6, 239sr231 (2014).
24. Rudd, J. H. & Fayad, Z. A. Imaging atherosclerotic plaque inflammation. Nat Clin Pract Cardiovasc Med 5 Suppl 2, S11-17 (2008).
25. Winter, P. M. et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108, 2270-2274 (2003).
26. Winter, P. M. et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26, 2103-2109 (2006).
27. Paeng, J. C. et al. Feasibility and kinetic characteristics of (68)Ga-NOTA-RGD PET for in vivo atherosclerosis imaging. Ann Nucl Med 27, 847-854 (2013).
28. Beer, A. J. et al. PET/CT imaging of integrin alphavbeta3 expression in human carotid atherosclerosis. JACC Cardiovasc Imaging 7, 178-187 (2014).
29. Gaertner, F. C., Kessler, H., Wester, H. J., Schwaiger, M., Beer, A. J. & Radiolabelled, R. G. D. peptides for imaging and therapy. Eur J Nucl Med Mol Imaging 39 Suppl 1, S126-138 (2012).
30. Schottelius, M., Laufer, B., Kessler, H. & Wester, H. J. Ligands for Mapping alpha(v)beta(3)-Integrin Expression in Vivo. Accounts Chem Res 42, 969-980 (2009).
31. Lee, B. C. et al. Synthesis and biological evaluation of RGD peptides with the Tc-99m/Re-188 chelated iminodiacetate core: highly enhanced uptake and excretion kinetics of theranostics against tumor angiogenesis. RSC Adv 3, 782-792 (2013).
32. Haubner, R. et al. Radiolabeled alpha(v)beta(3) integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 40, 1061-1071 (1999).
33. Lee, K. H. et al. Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs. J Nucl Med 46, 472-478 (2005).
34. Alves, S. et al. In vitro and in vivo evaluation of a novel Tc-99m(CO)(3)-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-D-Tyr-Lys). Bioconjugate Chem 18, 530-537 (2007).
35. Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L. & Ross, R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 11, 443-457 (1994).
36. Tarkin, J. M., Joshi, F. R. & Rudd, J.H.F. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol, 14, 133-140 (2014).